Ipsen Shares Climb 2.26% Following a Crucial European Approval in Pediatric Oncology

Significant Regulatory Approval Boosts Ipsen's Stock

Ipsen's stock has risen by 2.26% to €163.00, while the CAC 40 has dropped by 0.39% in the session. This rebound occurs on the very day the European Commission granted a conditional marketing authorization for Ojemda (tovorafenib), a treatment for children with low-grade brain gliomas carrying a BRAF gene alteration, after previous treatments failed. This approval extends across all 27 European Union countries, as well as Iceland, Liechtenstein, and Norway.

This green light represents a strategic milestone for the group, strengthening its portfolio in rare oncology. It is part of an already remarkable stock market journey: over three months, the stock has gained 22.74%, and its annual increase reaches 79.71%. The upcoming general assembly on May 13, followed by the publication of the semi-annual results on July 30, will be the next key dates for shareholders.

Technical Analysis Shows a Strong Uptrend

Technically, Ipsen is significantly above its 50-day moving average (€157.32) and even more so above its 200-day average (€128.91), indicating a well-established upward trend in the medium and long term. The current price of €163.00 is in the upper part of the Bollinger bands, at 61% of the range between the lower bound (€148.44) and the upper bound (€172.36), without indicating an overbought zone. The RSI, positioned at 50, remains neutral and does not show any excessive directional tension.

The stock has identified support at €148.40, close to the lower Bollinger band, while the nearest resistance is at €169.70. Breaking through this threshold could pave the way for an approach to the upper bound. It is worth noting that the very low beta of the stock (0.09) confirms its significant decoupling from the market, as illustrated by today's session: Ipsen gains more than 2% while the SBF 120 falls by 0.36% and peers like UCB lose 1.74%.